API | nemolizumab

nemolizumab Report issue

Biologics mAb Experimental

AACT MeSH

Active Ingredient History

NOW

Nemolizumab is an experimental drug for the treatment of itching in people with atopic dermatitis. It is a monoclonal antibody that blocks the interleukin-31 receptor A. Results of a Phase II clinical trial were published in March 2017. ^Wikipedia

Chemistry

SMILES: Missing data
InChIKey: Missing data
Mol. Mass: Missing data
ALogP: Missing data
ChEMBL Molecules: Missing data

More Chemistry

Pharmacology

Mechanism of Action:
Multi-specific: No
Black Box: Missing data
Availability: Missing data
Delivery Methods: Missing data
Pro Drug: Missing data

cim331 | nemolizumab

Organizations (3)

Research & Development (3)

Organization	Org Type	FDA approvals	Clinical Trials involvement	Org ID	Force Sort

Marketing (0)

Organization	Org Type	FDA approvals	Clinical Trials involvement	Org ID	Force Sort

Indications (6)

Approved Indications (0)

Experimental Indications - Clinical Trial Phases 1-4 (6)

Chronic Kidney Disease-Mineral and Bone Disorder (Phase 2/Phase 3)

Dermatitis, Atopic (Phase 3)

Healthy Volunteers (Phase 1)

Prurigo (Phase 3)

Renal Insufficiency, Chronic (Phase 2/Phase 3)

Scleroderma, Systemic (Phase 2)

Overview

Highest Phase: Phase 3
# of Trials: 18
# of Trial Organizations: 3

Trials by Phase

Trial	Phase	Start Date	Organizations	Indications

Feedback

Data collection and curation is an ongoing process for CDEK - if you notice any information here to be missing or incorrect, please let us know! When possible, please include a source URL (we verify all data prior to inclusion).

Report issue